FUNDING
AIDS
INFECTIOUS DISEASES, ALLERGY, AIDS, ABUSE, EMERGENCY
This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) through R01‐AI095068, the National Institute of General Medical Sciences (NIGMS) through R01‐GM136724 and by the HIV Prevention Trials Network (HPTN), which is sponsored by the NIAID under Cooperative Agreements UM1‐AI068619, UM1‐AI068617 and UM1‐AI068613, with funding from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Additional support was provided by the Division of Intramural Research, NIAID. Additional funding for the HPTN 071 (PopART) trial was provided by the International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation, as well as by NIAID, the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH), all part of NIH. RH also received support from the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, which is also part of the EDCTP2 programme supported by the European Union (MR/R010161/1).